Now live: European new issue coverage and historical data, for free. → Explore All Content & Delivery Channels
Log In
No results found for "".

Deal Details

C/PIndustryStatusTicker(s)Issuer(s)Size(m)TranchesRegionDate
IGC
HLTH
PRCD
TMO
Thermo Fisher Scientific (Finance I) BV€2,800
3USOA
Nov 9, 2021
currency
EUR
size (m)
550.000
maturity
Nov 18, 2023
type
Zero
tenor
2.000
call
-
registration
SEC Registered
benchmark
Swaps
ranking
Sr. Unsecured
moody's
Baa1
s&p
BBB+
fitch
BBB+
size description
-
re-open/tap
No
ipt
MS+35 a
ipt-pxd
-
guidance
-
spread
20
coupon
0%
spread set
-
price
100.32100
yield
-0.16%
book size (m)
1,300
peak book (m)
-
x-covered
2.36
book attrition
-
nic
5
billing & delivering
-
active leads
-
joint leads
BAM, BNP, BRC, CSG, ...
passive leads
-
co-managers
-
coordinating managers
-
book size (m)
1,300
peak book (m)
-
x-covered
2.36
book attrition
-
nic
5
billing & delivering
-
active leads
-
joint leads
BAM, BNP, BRC, CSG, ...
passive leads
-
co-managers
-
coordinating managers
-
currency
EUR
size (m)
1,700.000
maturity
Nov 18, 2023
type
Floating
tenor
2.000
call
-
registration
SEC Registered
benchmark
3mEu
ranking
Sr. Unsecured
moody's
Baa1
s&p
BBB+
fitch
BBB+
size description
-
re-open/tap
No
ipt
3mEu+35 a
ipt-pxd
-
guidance
-
spread
20
coupon
3mEu+20
spread set
-
price
100.74400
yield
-
book size (m)
2,750
peak book (m)
-
x-covered
1.62
book attrition
-
nic
8
billing & delivering
-
active leads
-
joint leads
BAM, BNP, BRC, CSG, ...
passive leads
-
co-managers
-
coordinating managers
-
book size (m)
2,750
peak book (m)
-
x-covered
1.62
book attrition
-
nic
8
billing & delivering
-
active leads
-
joint leads
BAM, BNP, BRC, CSG, ...
passive leads
-
co-managers
-
coordinating managers
-
currency
EUR
size (m)
550.000
maturity
Nov 18, 2025
type
Zero
tenor
4.000
call
-
registration
SEC Registered
benchmark
Swaps
ranking
Sr. Unsecured
moody's
Baa1
s&p
BBB+
fitch
BBB+
size description
-
re-open/tap
No
ipt
MS+45 a
ipt-pxd
-
guidance
-
spread
23
coupon
0%
spread set
-
price
99.86800
yield
0.033%
book size (m)
2,300
peak book (m)
-
x-covered
4.18
book attrition
-
nic
5
billing & delivering
-
active leads
-
joint leads
BAM, BNP, BRC, CSG, ...
passive leads
-
co-managers
-
coordinating managers
-
book size (m)
2,300
peak book (m)
-
x-covered
4.18
book attrition
-
nic
5
billing & delivering
-
active leads
-
joint leads
BAM, BNP, BRC, CSG, ...
passive leads
-
co-managers
-
coordinating managers
-
Tranche Comments
2 yr: Book size: 1300; Registration: SEC Registered; Comments: EUR2.5bn 3-tranche bmk snr unsec SEC Registered. Baa1/BBB+/BBB+. Barc/MS/BofA/Citi/Miz. 2yr EUR550m MS+35 area, set MS+20, 2yr EUR1.7bn 3mE+35 area, set 3mE+20, 4yr sustainable EUR550m MS+45 area set MS+23. Bks > 1.3bn/2.75bn/2.3bn, Sizes from exp 500m/1.5bn/500m. OBL 0% Oct-23 #178 B+62.2 @101.52 (HR 102%) , OBL 0% Oct-25 #182 B+68.9 @102.61 (HR 99%) LEI: 549300SM0PJC1F3RPL91; 2 yr: Book size: 2750; Registration: SEC Registered; Comments: EUR2.5bn 3-tranche bmk snr unsec SEC Registered. Baa1/BBB+/BBB+. Barc/MS/BofA/Citi/Miz. 2yr EUR550m MS+35 area, set MS+20, 2yr EUR1.7bn 3mE+35 area, set 3mE+20, 4yr sustainable EUR550m MS+45 area set MS+23. Bks > 1.3bn/2.75bn/2.3bn, Sizes from exp 500m/1.5bn/500m. OBL 0% Oct-23 #178 B+62.2 @101.52 (HR 102%) , OBL 0% Oct-25 #182 B+68.9 @102.61 (HR 99%) LEI: 549300SM0PJC1F3RPL91; 4 yr: Book size: 2300; Redemption: 2025-10-18; Registration: SEC Registered; Comments: EUR2.5bn 3-tranche bmk snr unsec SEC Registered. Baa1/BBB+/BBB+. Barc/MS/BofA/Citi/Miz. 2yr EUR550m MS+35 area, set MS+20, 2yr EUR1.7bn 3mE+35 area, set 3mE+20, 4yr sustainable EUR550m MS+45 area set MS+23. Bks > 1.3bn/2.75bn/2.3bn, Sizes from exp 500m/1.5bn/500m. OBL 0% Oct-23 #178 B+62.2 @101.52 (HR 102%) , OBL 0% Oct-25 #182 B+68.9 @102.61 (HR 99%) LEI: 549300SM0PJC1F3RPL91;
Deal Comments
Sustainable Bond. Active Bookrunners: BRC(B&D) (5 yr), MOS(B&D) (2yr FXD), BAM, CTI(B&D) (2 yr FRN), MIZ. Passive Bookrunners: BNP, CSG, DEU, HSB, ING, MUF, SMB, USB, WFS
Guarantor(s)
Thermo Fisher Scientific Inc
Use of Proceeds
M&A and general corporate purposes

Commentary

Explore all other Commentary & Deal Flow

Deal Flow

Explore all other Commentary & Deal Flow
We use functional cookies to make this site work properly and marketing cookies to personalize content. By continuing or clicking "Ok", you consent to our use of cookies. See our Cookie Policy for more information.
By continuing, you agree to FINSIGHT's Terms of Use and Privacy Policy.